|
|
|
|
| LEADER |
02194nam a2200313 u 4500 |
| 001 |
EB002001807 |
| 003 |
EBX01000000000000001164708 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Daptomycin for vancomycin-resistant enterococcal infection
|h Elektronische Ressource
|b a review of the clinical effectiveness, cost-effectiveness and guidelines
|
| 246 |
3 |
1 |
|a Daptomycin for VRE infections
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2016, 14 January 2016
|
| 300 |
|
|
|a 1 PDF file (22 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Comparative Effectiveness Research
|
| 653 |
|
|
|a Bacteremia / drug therapy
|
| 653 |
|
|
|a Daptomycin
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Anti-Bacterial Agents / therapeutic use
|
| 653 |
|
|
|a Vancomycin-Resistant Enterococci / drug effects
|
| 653 |
|
|
|a Vancomycin Resistance
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK343928
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Vancomycin-resistant enterococci (VRE) infections can mostly be treated with antibiotics other than vancomycin, and laboratory tests can be performed to identify optimal treatment regimens. Daptomycin is one antibiotic with known in vitro activity against VRE. Daptomycin and vancomycin have different bactericidal mechanisms of action; specifically, daptomycin works by binding or inserting into the outer membrane, while vancomycin inhibits cell wall synthesis. Other possible options for treating VRE include linezolid, tigecycline, oritavancin, televancin, and a combination of quinupristin and dalfopristin. This Rapid Response report aims to review the comparative clinical- and cost-effectiveness of daptomycin for patients with VRE infections. Evidence-based guidelines on the optimal use of daptomycin in patients with VRE infections will also be summarized
|